By Dhirendra Tripathi
Investing.com – Pfizer stock (NYSE: PFE ) fell 3.5% in premarket trading Tuesday after the company’s fourth-quarter revenue fell short of expectations, revealing struggles in its non-Covid business.
Excluding contributions from Comirnaty and Paxlovid, revenue fell 2% on the year.
Sales of its pneumococcal conjugate vaccine Prevnar fell 27% in the U.S. as schedule of government purchases changed while Covid vaccinations were prioritized.
Shipments of its anti-smoking tablets Chantix remained suspended and weighed on the results. Tests had shown an unacceptably high level of a carcinogen in the medication. Sales of cancer drug Sutent were lower due to entry of competition on loss of exclusivity.
Fourth-quarter revenue more than doubled to nearly $24 billion as sales of its Covid vaccines exceeded expectations. Pfizer blamed the shortfall in revenue, excluding Covid treatments, to fewer selling days during the period compared to last year.
Comirnaty contributed $12.5 billion in direct sales and alliance revenue during the quarter. Germany’s BioNTech (NASDAQ: BNTX ) is Pfizer’s partner in marketing the Covid vaccines and they split the profits from it equally.
The company’s record-high forecast of $100 billion in 2022 revenue at the midpoint of its guidance range failed to cover the disappointment of its fourth-quarter numbers. The annual outlook includes revenue of around $32 billion from Comirnaty and $22 billion from Paxlovid.
Pfizer aims to make more than 4 billion doses of the shot in 2022. That compares with last year's 3 billion doses. Pfizer forecast 2022 sales of $98 billion to $102 billion, also below estimates of $105.48 billion.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.